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Innovations are urgently required for clinical development of antibacterials against multidrug-resistant organisms. Therefore, a 
European, public-private working group  (STAT-Net; part of  Combatting Bacterial Resistance in Europe [COMBACTE]), has 
reviewed and tested several innovative trials designs and analytical methods for randomized clinical trials, which has resulted in 8 
recommendations. The first 3 focus on pharmacokinetic and pharmacodynamic modeling, emphasizing the pertinence of popula-
tion-based pharmacokinetic models, regulatory procedures for the reassessment of old antibiotics, and rigorous quality improvement. 
Recommendations 4 and 5 address the need for more sensitive primary end points through the use of rank-based or time-dependent 
composite end points. Recommendation 6 relates to the applicability of hierarchical nested-trial designs, and the last 2 recommen-
dations propose the incorporation of historical or concomitant trial data through Bayesian methods and/or platform trials. Although 
not all of these recommendations are directly applicable, they provide a solid, evidence-based approach to develop new, and estab-
lished, antibacterials and address this public health challenge.
Keywords. randomized clinical trials; multidrug-resistant organisms; novel biostatistical methods; clinical trial design; 
antibacterial drug development.
There is a gap between the number of new antibacterials in 
research and development (R&D) and the medical need caused 
by the increasing prevalence of infections by multidrug-resistant 
organisms (MDROs) [1]. In a 2014 survey [2], pharmaceutical 
industry professionals provided their opinion on the main chal-
lenges underlying this discrepancy. Most frequently, they indi-
cated the low return on investment for antibacterials, followed by 
the lack of new regulatory pathways for antibacterial medicines 
that address a high unmet medical need, such as novel treatment 
options against MDROs. Importantly, innovative trial designs 
were seen as an important tool to promote R&D efforts for new 
antibacterials. Since this survey was conducted, political aware-
ness of the need to encourage R&D for new antibacterials has 
risen enormously, with regulatory guidance being updated and 
international harmonization efforts underway [3–5]. However, 
critical to these processes is the need to advance and optimize 
trial design and make more effective use of the available data, 
so as to accelerate antibacterial approval and ensure appropriate 
use of established antibiotics active against MDROs.
Indeed, in the area of MDRO therapeutics, where the num-
ber of patients with resistant infections for each specific indi-
cation is generally still small, large studies are impossible or 
impractical [6]. Within traditional randomized controlled trials 
(RCTs), outcomes for patients with susceptible and resistant 
infections are combined, and although the subset of infections 
with resistant pathogens is presented separately, sample size is 
often insufficient. As a consequence, assessment of safety and 
effectiveness of new agents against MDROs is challenging, and 
without novel trial designs, which make better use of the avail-
able data, progress is difficult. Rex et  al [7] have proposed a 
“totality-of-evidence” approach to resolve the impasse; instead 
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of 2–3 large phase II and III trials, multiple sources of data 
could contribute to the evidence base of the clinical benefit of 
a new drug, including smaller RCTs. However, this approach 
needs to be supported by robust pharmacokinetic and phar-
macodynamic (PK/PD) data on optimal dosing of patients and 
the ability to design, analyze, and interpret clinical trials as effi-
ciently as possible.
In 2013, the Innovative Medicines Initiative (IMI; www.imi.
europa.eu) established the Combatting Bacterial Resistance in 
Europe consortium (COMBACTE; www.combacte.com) to 
conduct prospective clinical trials and refine clinical trial design 
for new treatments against MDROs [8]. The specific objective 
for STAT-Net (Workpackage 4)  was to deliver strategies that 
may yield more efficient phase II and III clinical trial programs, 
and to focus on 3 pillars: improved PK/PD modeling, enhanced 
end points, and innovative trial designs. In this white paper, we 
propose several innovative design and analysis strategies for 
regulatory and pragmatic clinical trials to support the evalua-
tion of new and established antibacterials against MDRO infec-
tions, and discuss their scientific robustness and feasibility.
METHODS
STAT-Net was initiated in response to the sixth call for pro-
posals issued by IMI in 2012 [9]. Subtopic 1A, Workpackage 
4, specified 3 research pillars, as described above, which were 
aligned with regulatory and scientific challenges at the time of 
writing. One of us (S. H.) assembled, through open invitation, a 
group of experts with strong track records in PK/PD, biostatis-
tics, Bayesian statistics, infectious diseases, intensive care med-
icine, epidemiology, and clinical development. Aligned with 
the IMI public-private partnership, pharmaceutical company 
partners joined to provide additional expertise. This group pro-
posed a description of work in line with the original call, which 
was granted by IMI in autumn 2012.
Between January 2013 and July 2017, systematic reviews, 
reanalyses of existing clinical trial data, and simulations have been 
carried out. Some of this work has already been peer reviewed and 
published [10–19]. The final recommendations presented here are 
based on this work, extensive discussions via teleconferences, and 
STAT-Net–specific and COMBACTE-wide meetings, and they 
have been approved by all authors. We created an objective scor-
ing system for each recommendation, which was approved by all 
partners (Table 1), and was used to score (1) alignment with the 
current regulatory framework; (2) feasibility of technical imple-
mentation, like the need for specific biostatistical or PK/PD skills; 
(3) ease of data interpretation; (4) ease of practical implementa-
tion at the clinical site; and (5) the strength of the evidence base 
for each recommendation (Table 2). Whenever disagreement con-
cerning a recommendation arose, recommendations and scoring 
were adapted until consensus was reached. Based on the average 
score, recommendations are presented as “strongly recommend,” 
“recommend,” “strongly suggest,” or “suggest.”
Table 1. Classification Table for the Recommendations
Classification
Alignment With Current 
Regulatory Framework
Ease of Technical 
Implementation
Ease of 
Interpretation
Ease of Practical 
Implementation Evidence Base Formulation
+ Adaptations in design  
AND analytical 
methods needed, 
currently not sup-
ported by regulatory 
authorities
Only by statistical 
or PK/PD experts 
familiar with the 
method
Very complex; 
requires statis-
tical expertise 
and experience 
with the method
Design and analytical 
methods require sig-
nificant adaptation of 
standard clinical trial 
protocols, AND extra 
data are required
Based on expert opinion, 
and/or external panel 
consensus.
“We suggest ..”
++ Adaptations in design  
OR analytical 
methods needed, 
currently not sup-
ported by regulatory 
authorities
Only applicable by 
statisticians or PK/ 
PD experts
Moderately com-
plex; statis-
tical expertise 
required
Design and analytical 
methods require 
moderate adapta-
tions of standard 
clinical trial protocols 
OR extra data are 
required
Based on encouraging 
results from simulations
“We strongly 
suggest…”
+++ Adaptations in end 
points, consulta-
tion with regulatory 
authorities required
Applicable by those  
experienced in 
applied statistical or 
PK/PD analysis
Moderately easy; 
clinical trial back-
ground required 
but no need 
for a statistical 
background
Design and analytical 
methods require 
small adaptations 
to specific parts of 
a standard clinical 
trial protocol, and 
no extra data are 
required
There is fair research- 
based evidence to sup-
port the recommenda-
tion; reanalysis of clinical 
trial data has provided 
encouraging results
“We recommend…”
++++ No obstacles for imple-
mentation identified, 
in line with current 
regulatory guidelines
Only basic statistical 
or PK/PD expertise 
required
Easy; no need 
for a statistical 
or clinical trial 
background
Standard clinical trial 
protocols can be 
applied, and no extra 
data are required
There is good research- 
based evidence to sup-
port the recommenda-
tion; it has already been 
applied and tested in 
clinical trials
“We strongly 
recommend…”
Abbreviation: PK/PD, pharmacokinetic and pharmacodynamic.
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Table 2. Recommendations and Their Classification Regarding Current Regulations, Implementation, Interpretation, and Evidence Basea
Recommendations
Alignment With Current 
Regulatory Framework
Ease of Technical 
Implementation Ease of Interpretation
Ease of Practical 
Implementation Evidence Base
Innovative biostatistical methods for PK/PD 
modeling
 1.  We recommend that phase II and III clin-
ical trials of new antibiotics, particularly 
those active against MDROs, always 
apply population PK models to describe 
and explain PK variability, optimize dose 
finding, and evaluate outcome data rela-
tive to exposure.
++++ +++ ++ +++ ++++
 2.  We recommend an EU-coordinated  
regulatory procedure for reassessment 
of old antibiotics and their licensing, 
particularly those active against MDROs, 
which addresses justification of dosing 
regimens and exposure-response data 
according to modern PK/PD principles. 
This should include description of PK/PD 
targets, development of population PK 
models, and reassessment of antibacte-
rial spectra.
++ +++ ++ +++ +++
 3.  We recommend that future clinical PK/ 
PD studies provide more robust results 
by a priori determination of the sample 
size, adjustment for known confounders 
of the exposure-response relationship, 
assessment of both microbiological and 
patient-oriented outcomes, and applica-
tion of appropriate statistical techniques.
++++ +++ +++ +++ +
Selection of novel and more sensitive primary 
outcomes for clinical trials
 4.  We recommend using rank-based com-
posite end points combining patient-ori-
ented and disease-related end points 
to assess new antibacterial therapies 
against MDROs.
+++ +++ +++ ++ ++
 5a.  We strongly suggest, in trials dealing 
with MDROs, applying multistate mod-
els to examine a range of  
time-dependent clinical outcomes in the 
primary analysis to better characterize 
the patient’s disease course.
++ + ++ ++ +++
 5b.  We strongly suggest, when applying 
multistate models, performing statis-
tical significance testing for the proba-
bility of being cured and alive over the 
entire treatment process rather than at 
the end of follow-up.
+ + ++ + +++
Innovative trial design in the absence of rapid 
diagnostics
 6.  We strongly suggest that trials aiming 
to assess the clinical benefit of a new 
therapy against MDRO pathogens should 
apply a hierarchical nested-trial design 
if a priori power calculations indicate 
feasibility.
++ ++ ++ ++ ++
Methods to incorporate historical clinical trial 
data
 7.  We strongly suggest that clinical trial 
investigators make use of the multitude 
of historical clinical trial data in the design 
and analysis of novel MDRO treatment 
trials.
++ ++ +++ ++ +++
 8.  We suggest the use of platform trials 
to study new antibacterial treatments 
against MDROs.
+ + ++ ++ +
Abbreviations: EU, European Union; MDROs, multidrug-resistant organisms; PD, pharmacodynamic; PK, pharmacokinetic.
aSee Table 1 for definitions of symbols +, ++, +++, and ++++.
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RESULTS
Innovative Biostatistical Methods for PK/PD Modeling
Recommendation 1 (Study Design)
We recommend that phase II and III clinical trials of new 
antibiotics, particularly those active against MDROs, 
always apply population PK (popPK) models to describe 
and explain PK variability, optimize dose finding, and 
evaluate outcome data relative to exposure.
Antibiotic efficacy, which determines microbiological cure, 
depends on the in vitro potency of the drug (usually expressed 
as the minimum inhibitory concentration [MIC]) and the in 
vivo exposure of the microorganism to the drug, which relies 
on the concentration-time profile (pharmacokinetics) and the 
dose. Owing to MIC and PK variability, dosing optimization for 
certain patient subgroups is essential to avoid poor outcomes 
from ineffective treatment or resistance selection with too low 
doses, or adverse events with too high doses [20].
Identification of efficacious dosing regimens based on pre-
clinical PK/PD analyses and phase I and II studies support the 
dosing rationale in phase II and III clinical studies [21]. An 
important aspect of preclinical PK/PD analyses is the identifica-
tion of a dominant drug-specific PK/PD index, which describes 
the exposure-response relationship (eg, the percentage of the 
dosing interval that the free drug concentration (fT)  remains 
above the MIC, fT > MIC) and the minimal index value that 
ensures a high probability of efficacy (the PK/PD target, eg, 50% 
fT > MIC). In phase I studies, the PK of several dosing regimens 
is explored in healthy volunteers. Subsequently, in phase II and 
III studies, popPK models can be further developed to describe 
and explain PK variability in the heterogeneous target popula-
tion [21]. Simulations based on popPK models can be used to 
determine the probability of target attainment of various dos-
ing regimens in specific subpopulations, and thereby improve 
the efficiency of phase II and III studies. PopPK data, combined 
with MICs and outcome data, can also be used to refine pre-
clinical exposure-response relationships and identify clinically 
relevant PK/PD indices and targets.
This recommendation is highly evidence based and in align-
ment with the current regulatory framework (Table 2) [21, 22]; 
however, it is not yet fully applied for all recently approved anti-
biotics. Another drawback is that evaluation of data is often 
restricted to blood levels; data for other relevant body sites 
are also important, but interpretation for these body sites still 
remains uncertain. This recommendation is applicable for all 
infections, including those caused by MDROs (Table 3).
Recommendation 2 (Regulatory Procedures)
We recommend a European Union (EU)–coordinated 
regulatory procedure for reassessment of old antibiot-
ics and their licensing, particularly those active against 
MDROs, which addresses justification of dosing regimens 
and exposure-response data according to modern PK/PD 
principles. This should include description of PK/PD tar-
gets, development of popPK models, and reassessment of 
antibacterial spectra.
Many currently used antibiotics have been available clinically 
for many years, and long before current PK/PD principles and 
popPK modeling programs were used in drug evaluation [20]. 
PK analyses were based on noncompartmental or simple com-
partmental methods without covariate investigation. PK/PD 
targets were mostly unknown, and probability of target attain-
ment simulations were not performed. The optimal dosing 
regimens of many old antibiotics therefore remain unknown, 
which makes the probability of efficacy attainment uncertain. 
Moreover, the antibacterial spectrum of old antibiotics is often 
poorly defined, as changes in resistance epidemiology have not 
been systematically studied.
Reanalysis of old PK data may support dosing optimization 
of old antibiotics, provided the PD target is or will be estab-
lished. For example, within the framework of STAT-Net, a 
popPK model using 45-year-old amoxicillin drug concentra-
tion data was developed, and new dosing recommendations 
were published based on probability of target attainment sim-
ulations [10]. Unfortunately, the retrieval of such old data can 
be cumbersome. Alternatively, new PK studies of old antibiotics 
can be performed, for example, in the EU project AIDA (www.
aida-project.eu). Unfortunately, even though new popPK mod-
els are being developed, PK/PD targets are still lacking for many 
old antibiotics [20]. Thus, developing rational dosing recom-
mendations for all old antibiotics can be complex.
This recommendation is evidence based (Table  2), but it 
does not align with current regulatory approaches, because a 
coordinated redevelopment procedure including updating of 
summary of product characteristics is currently unavailable 
[20]. However, some studies are performed in EU and National 
Institutes of Health projects (COMBACTE, AIDA, National 
Institutes of Health; www.nih.gov/news-events/news-releases/
nih-funds-four-clinical-trials-fight-antibiotic-resistance), 
which may provide a suitable basis. This recommendation is 
applicable for all infections, including those caused by MDROs 
(Table 3).
Recommendation 3 (Study Design)
We recommend that future clinical PK/PD studies pro-
vide more robust results by a priori determination of the 
sample size, adjustment for known confounders of the 
exposure-response relationship, assessment of both micro-
biological and patient-oriented outcomes, and application 
of appropriate statistical techniques.
Although clinical PK/PD studies of antibiotics are always 
performed, their design and analysis have had limitations. 
Consequently, guidance on dosing regimens does not always 
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Table 3. Applications and Possible Benefits and Disadvantages for Each Recommendation
Recommendation Type of Trial Indications Population Benefits Disadvantages
Innovative biostatistical methods for PK/PD 
modeling
 1.  We recommend that phase II and III  
clinical trials of new antibiotics, par-
ticularly those active against MDROs, 
always apply population PK models to 
describe and explain PK variability, opti-
mize dose finding, and evaluate  
outcome data relative to exposure.
PK/PD analyses with  
PK and PK/PD data  
from phase I, II,  
and III studies;
PK/PD target based on pre-
clinical and clinical data
All infections All Optimized dosing,  
increasing the likelihood 
of detecting true efficacy 
in RCTs, decreasing the 
likelihood of emergence 
of resistance
Additional patient sampling  
required; extra costs for RCT 
sponsors
 2.  We recommend an EU-coordinated  
regulatory procedure for reassessment 
of old antibiotics and their licensing,  
particularly those active against 
MDROs, which addresses  
justification of dosing regimens and 
exposure-response data according to 
modern PK/PD principles. This should 
include description of PK/PD targets, 
development of population PK models, 
and reassessment of antibacterial 
spectra.
PK/PD analyses with PK 
 and PK/PD data from 
phase I, II, and III  
studies;
PK/PD target based on pre-
clinical and clinical data
All infections All Optimized dosing and  
indications of old  
antibiotics, increasing  
the likelihood of  
detecting true efficacy  
in RCTs, decreasing the  
likelihood of emergence 
of resistance
Need for alignment with regula-
tory authorities; new licensing 
required; public funding for 
reassessment studies required
 3.  We recommend that future clinical  
PK/PD studies provide more robust 
results by a priori determination of  
the sample size, adjustment for  
known confounders of the exposure- 
response relationship, assessment  
of both microbiological and patient- 
oriented outcomes, and application  
of appropriate statistical techniques.
PK/PD analyses with PK and 
PK/PD data from phase I, 
II, and III studies.
PK/PD target based on pre-
clinical and clinical data.
All infections All More reliable PK/PD data, 
optimized dosing, 
increasing the likelihood 
of detecting true efficacy 
in RCTs, decreasing the 
likelihood of emergence 
of resistance
Additional patient sampling  
required; extra costs for RCT 
sponsors
Selection of novel and more sensitive pri-
mary outcomes for clinical trials
 4.   We recommend using rank-based  
composite end points combining 
patient-oriented and disease-related  
end points to assess new therapies 
against MDROs.
All All infections, espe-
cially those with  
low mortality
All More meaningful, and  
sensitive end points, 
increasing the likelihood 
of true positive findings 
in RCTs
End points could become more 
subjective; end points may be 
more difficult to interpret; it 
can be difficult to establish an 
acceptable NI or superiority 
margin
 5a.   We strongly suggest, in trials dealing 
with MDROs, applying multistate  
models to examine a range of time- 
dependent clinical outcomes in the pri-
mary analysis to better characterize  
the patient’s disease coursea.
All Those with moder-
ate to high  
mortality  
rates
Populations with  
moderate to high 
mortality rates
More meaningful, and  
sensitive end points, 
increasing the likelihood 
of true-positive findings 
in RCTs
Composite end points may be 
more difficult to interpret; it 
can be difficult to establish an 
acceptable NI or superiority 
margin
Innovative trial design in the absence of  
rapid diagnostics
 6.  We strongly suggest that trials aiming  
to assess the clinical benefit of a new 
therapy against MDRO pathogens 
should apply a hierarchical nested-trial 
design if a priori power calculations  
indicate feasibility.
NI trials All MDROs Statistically sound results 
for treatment efficacy 
in the MDRO subgroup 
without the need for rapid 
diagnostics
Large sample of non-MDRO 
patients required
Methods to incorporate historical clinical 
trial data
 7.  We strongly suggest that clinical trial 
investigators make use of the multitude 
of available historical clinical trial data in 
the design and analysis of novel MDRO 
treatment trials.
All All All RCTs can include a lower 
number of patients, but 
remain powered, and 
existing evidence is effi-
ciently used
Increased type I error; need for 
historical RCT data, which may 
be difficult to obtain
 8.  We suggest the use of platform trials 
to study new antibacterial treatments 
against MDROs.
All All All Increasing the efficiency  
of RCTs by using the 
same patients for  
multiple RCTs
Large database and high work-
load, which may not be used 
eventually; potential conflicts 
between different study spon-
sors and/or companies
Abbreviations: EU, European Union; MDRO, multidrug-resistant organism; NI, noninferiority; PD, pharmacodynamic; PK, pharmacokinetic; RCT, randomized controlled trial.
aThis also holds for recommendation 5b, as it is an extension of recommendation 5a.
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have a strong evidence base, and to maximize the possibility of 
successful clinical outcomes and pathogen eradication, espe-
cially in the case of MDROs, more robust data are needed.
We conducted a systematic review of clinical PK/PD studies 
published since 1980, which related a calculated PK/PD index 
to the probability of a clinical or microbiological response [18]. 
After deduplication, 6096 records were reviewed, resulting in 
the final inclusions of 85 articles containing 97 PK/PD analyses. 
Only 3 of 97 studies included a sample size calculation, and as 
such it cannot be determined whether clinical meaningful results 
would have been detected if present. Less than half of the stud-
ies included adjusted analyses for known confounders, including 
physiological patient characteristics, infection characteristics, 
and concurrent treatments. About half of the studies focused 
on clinical response, and the other half reported bacteriological 
response, but in most cases both would be important. Clinical 
response is the most important outcome to the patient, but bac-
teriological response measures the direct effect of the antibiotic. 
From an analytical perspective, only 61 of 97 studies reported 
some form of regression, performed time-to-event analysis, or 
used the Hill  (Emax, maximum drug effect) equation to look at 
the association between PK/PD index and outcome. To pre-
vent inappropriate interpretation and multiplicity errors caused 
by analyzing a number of factors in a data-dependent way, we 
recommend that preapproved analysis plans should be imple-
mented. These should ideally be based on the recently published 
regulatory guidance document EMA/CHMP/594085/2015 
[21], which took into consideration the above-described work 
and emphasizes application of the most appropriate methods. 
Furthermore, presentation of confidence intervals around stated 
effects will guard against inappropriate interpretation of under-
powered analyses. This recommendation is based on expert 
opinion, is moderately easy to apply (Table 2), and is applicable 
for all infections including those caused by MDROs (Table 3).
Selection of Novel and More Sensitive Primary Outcomes for Clinical Trials
Recommendation 4 (Study Design/Analysis)
We recommend using rank-based composite end points 
combining patient-oriented and disease-related end points 
to assess new therapies against MDROs.
At present, an ideal end point that would allow assessment of 
the efficacy of new therapies against MDRO is still lacking [16]. 
Patient-oriented end points, such as mortality or quality of life, 
are robust and matter directly to patients [23]. However, they 
also rely on several other noninfectious, confounding factors. 
Moreover, they require large sample sizes for noninferiority 
(NI) testing, with clinically unacceptable NI margins [16]. On 
the other hand, disease-oriented primary end points, such as 
clinical cure or organ failure–free days, are more sensitive and 
require smaller samples, but these are not always unequivocally 
linked to true patient benefit [16].
In this context, composite end points seem to be worthy 
of further study [16], especially if they are easy to use and give 
appropriate priority to the more clinically important events (eg, 
mortality). New methods for analyzing composite end points have 
already been reported [24, 25], and applied [26, 27]. In a recent 
Delphi process, 26 experts in the field of severe nosocomial pneu-
monia confirmed that such a composite end point, combining 
patient-oriented and disease-related end points, was expected to 
be the best method for assessing antibacterial efficacy in future 
clinical trials. This could be extended by applying multistate mod-
els (recommendation 5a), or a hierarchical nested-trial design 
(HNTD) (recommendation 6). The development of a rank-based 
composite end point needs to be planned before RCTs start and 
discussed with regulatory authorities. It is technically feasible to 
apply, but interpretation is complex (Tables 2 and 3).
Recommendation 5a (Study Design/Analysis)
We strongly suggest, in RCTs dealing with MDROs, apply-
ing multistate models to examine a range of time-depen-
dent clinical outcomes in the primary analysis to better 
characterize patients’ disease course.
Food and Drug Administration and European Medicines 
Agency guidelines have suggested the use of different primary 
end points in clinical trials evaluating treatment for patients 
with hospital- or ventilator-associated pneumonia, end points 
that include either a clinical outcome at the test of cure (TOC) 
visit or all-cause mortality at a specific point in time [28]. As 
discussed above, composite end points combining these clin-
ical important events could be more informative. On top of 
that, validity could be improved by considering the occurrence 
of events over time, instead of assessing them at a predefined 
time interval.
If cure and death end points are of particular interest, both 
measures of clinical benefit can be simultaneously accounted 
for in a multistate framework using the coprimary end point 
“get cured and stay alive over time.” The application of this type 
of analysis has been illustrated by using data from a recently 
published trial on patients with hospital- or ventilator-asso-
ciated pneumonia [15] and can be adapted to more complex 
disease histories, for example in patients with Clostridium dif-
ficile infection [14]. The application of such multistate models 
has the advantage of avoiding common survival biases (which 
occur if one deletes or censors death outcomes when studying 
cure), because ignoring time dependency may lead to overes-
timated or underestimated efficacy. Furthermore, it provides 
patient-relevant information about being cured and staying 
alive, instead of providing cure rates and mortality rates sepa-
rately. This recommendation requires specific statistical exper-
tise but can be applied to many potential MDRO treatment 
indications in both the design and analytical phases of RCTs 
(Tables 2 and 3).
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Recommendation 5b (Study Design/Analysis)
We strongly suggest, when applying multistate models, 
performance of statistical significance testing for the prob-
ability of being cured and alive over the entire treatment 
process rather than at the end of follow-up.
Traditionally, the hypothesis tested in RCTs uses the data 
obtained at the end of follow-up (eg, at the TOC visit). So far, no 
method has been validated that statistically tests NI or superior-
ity for a multistate end point demonstrating a treatment effect 
over the complete treatment process instead of merely at the 
end of follow-up.
We applied an innovative resampling technique to construct 
1-sided simultaneous confidence bands to test the difference in 
probabilities of being cured and alive between study arms [29, 
30], which performed well [13]. This provides a comprehensive 
picture of the time-dynamic effect of the entire treatment pro-
cess while preserving the desired α-level for statistical testing, 
resulting in a much stronger NI or superiority statement.
This recommendation is promising for the analysis of future 
RCTs, although it involves statistical expertise for implemen-
tation. Moreover, NI margins are difficult to establish, given 
their reliance on historical data of the effects without treatment. 
Discussions with regulatory authorities would be required to 
agree on an acceptable NI margin for this novel outcome mea-
sure (Table 2).
Innovative Trial Design in the Absence of Rapid Diagnostic Tests
Recommendation 6 (Study Design/Analysis)
We strongly suggest that trials aiming to assess the clinical 
benefit of a new therapy against MDRO pathogens should 
apply an HNTD if a priori power calculations indicate 
feasibility.
Superiority trials for new antibacterials targeting MDROs are, 
in general, considered infeasible [6]. It is usually impossible to 
select a MDRO subgroup at the time of randomization, because 
this usually occurs before standard organism susceptibility test-
ing is available. Rapid diagnostic testing would be very useful 
in this respect, but unfortunately rapid antibiotic susceptibility 
testing has not yet developed to a level that would make appli-
cation for RCTs feasible. If a new drug against MDROs were to 
be tested among a mixed patient group, with susceptible and 
MDRO infections, the chances of showing superiority is prob-
ably low, especially if the proportion of patients infected with 
MDROs is low. Therefore, NI trials have become the standard in 
this area, with limited data about clinical benefit for the MDRO 
patient subgroup.
The HNTD [31] is an innovative approach of addressing clin-
ical benefit for patients with susceptible infections and patients 
with MDRO infections within a single RCT. The HNTD originally 
suggests power calculations to be aligned with inference hierarchy, 
and thus sample size calculations will be based on the overall NI 
testing. In our simulations, we observed that demonstration of 
superiority in the MDRO subgroup can become practically infea-
sible if the sample size of this subgroup is small. The power impli-
cations of designing the trial on the basis of the superiority test 
in the MDRO subgroup should therefore be explored in advance. 
This is especially important from an ethical point of view, 
because it will indicate the likelihood of success of a RCT for 
the targeted MDRO subgroup, which should be a criterion for 
patient participation, just like expected beneficence for the sub-
group of patients with susceptible infection. Nevertheless, hier-
archical approaches should be considered whenever feasible, 
because they can provide valuable information for both the sus-
ceptible and MDRO subgroups. Possibly, a combination with 
rank-based composite end points (recommendation 4)  could 
make this approach more powerful. Application of this recom-
mendation is moderately complex, should be discussed with 
regulatory authorities before application, and requires a large 
sample of MDRO patients (Tables 2 and 3).
Methods to Incorporate Historical Clinical Trial Data
Recommendation 7 (Study Design/Analysis)
We strongly suggest that clinical trial investigators make 
use of the multitude of available historical clinical trial data 
in the design and analysis of novel MDRO treatment trials.
As discussed earlier, in most trials it is difficult to prospectively 
identify a large number of patients with MDRO infections and 
thus adequately power RCTs. Historical data from previous 
studies could be used more effectively to make the preparation 
and conduct of clinical trials more feasible and efficient.
Historical data are already used to help justify NI margins, but 
they can also be included in a Bayesian approach by using preex-
isting data to incorporate knowledge about possible trial results. 
Where several trials have been conducted with a similar or iden-
tical treatment to the control arm of the new trial, a meta-anal-
ysis based on these data can be performed, and a mathematical 
expression of the prior knowledge regarding control efficacy can 
be constructed. These priors can be interpreted as historical con-
trol patients, and when used alongside clinical trial patients can 
reduce the number of patients needed in the RCT, or increase the 
power of a given comparison [32, 33]. The new trial can be con-
ducted using a traditional design [34, 35] or an adaptive design, 
where the sample size or randomization ratio can be adjusted 
based on interim analyses to optimize power [33, 36].
This method highly depends on the quality of historical data, 
detail of publicly available data, and possible time-dependent 
changes in medical care. It also requires extensive communi-
cation between the sponsor and regulatory agency to agree on 
the prior distribution and acceptable type I and II error rates in 
the context of the efficiencies gained with such a design. This 
recommended method is not limited to specific end points or 
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infection types, so it can be applied in any trial where relevant 
data are available (Tables 2 and 3).
Recommendation 8 (Study Design/Analysis)
We suggest the use of platform trials to study new antibac-
terial treatments against MDROs.
If no historical data exist (recommendation 7), there are other, 
more efficient ways to improve sample size. In a platform trial, 
investigators focus on the disease rather than any particular 
experimental therapy, and they can simultaneously, or subse-
quently, investigate multiple experimental and control treat-
ments, as a way to handle patient involvement as effectively as 
possible.
A key recommendation in the report issued by the President’s 
Council of Advisors on Science and Technology in the United 
States [37] is the establishment of a clinical trials infrastructure 
that would in turn support a “platform trial” for antibacterial 
agents [38–40]. Although there are notable operational hurdles 
(for example, finding/identifying patients), many of them are 
germane to the larger complexities of implementing clinical 
trials for antibacterials [37]. Initiating a single platform trial in 
this setting could therefore aid in managing some of these bar-
riers, similar to what has already been accomplished in therapy 
areas such as oncology and Alzheimer disease [41]. 
The efficiency of such a platform trial is driven by key design 
features. These include use of a shared control and incorpora-
tion of Bayesian methods to allow use of information across 
sites of infection and/or from historical data (recommendation 
7) in a single analysis, bearing in mind the general prerequisites 
for using Bayesian approaches, such as assuring similarity of 
historical to contemporary data [38, 42, 43]. This recommenda-
tion requires specific statistical expertise, and there is no real-
world experience yet for antibacterial development, but based 
on experiences in other medical fields it seems a promising 
alternative (Tables 2 and 3).
DISCUSSION
Innovations are urgently required in the field of antibacte-
rial development, especially for treatments against MDROs. 
The recommendations provided here could be instrumental to 
advances in this field. Although the proposed recommendations 
would not always be applicable within the same trial, not all of 
them align with current regulatory guidelines, and they differ 
regarding ease of implementation or interpretation and evidence 
base, they are all relevant to the debate supporting change.
In Table 2, the different recommendations were scored, show-
ing that, in general, recommendations for PK/PD studies have 
the strongest evidence base, and our view is that they should 
be implemented as soon as possible to improve drug dosing 
in RCTs. Bayesian methods, incorporating data from histori-
cal controls in new RCTs, can be successfully used to reduce 
the number of patients required for RCTs. They have already 
been applied to reanalyze clinical trial data, and regulatory 
applicability is promising, provided that the historical and con-
temporary data can be shown to be comparable. Rank-based 
composite, or time-dependent, end points are another way to 
improve statistical efficiency and provide more meaningful data 
at the same time. However, technical and practical implementa-
tion still present some challenges, and a regulatory framework 
to support this approach is still lacking. 
Our recommendations related to HNTDs and platform trials 
are the least pertinent. Although the HNTD approach has clear 
merit, it generally faces the huge challenge of recruiting sufficient 
patients with MDROs to support a meaningful superiority assess-
ment. Platform trials could efficiently provide data for multiple, 
concurrent or subsequent, control arms, by establishing a com-
mon clinical trials infrastructure, but practical implementation is 
challenging, particularly gaining commitment at the initiation of 
the platform trial. By increasing RCT efficiency, superiority trials 
could become more feasible, which would be preferable, consid-
ering the ethical issues associated with NI trials [44].
STAT-Net partners are already working on the evaluation and 
refinement of some of the proposed solutions. First, as an exten-
sion of recommendation 6, a novel HNTD is being evaluated, 
in which an alternative, more sensitive end point (statistically) 
is introduced for the subgroup of patients infected by resistant 
pathogens. Such an approach could curtail the required sample 
size for superiority testing in the subgroup. To maintain confi-
dence in the clinical benefit, the point estimate for the clinical 
end point of interest, as used in the NI assessment for the whole 
sample (ie, cure rate), should be similar as well. An example of 
a more statistically sensitive end point could be the regulatory 
approved end point of absolute reduction in skin lesions in skin 
and soft-tissue infections. This approach could be especially 
valuable for very rare MDROs.
Second, the application of multistate models (recommen-
dation 5) is being studied for combined end points other than 
cured and alive, for example, to be alive and not receiving 
mechanical ventilation in patients with acute respiratory dis-
tress. Study planning for more specific multistate end points 
will typically be simulation based [45]. Previous studies can be 
used to define the assumptions needed for these types of sim-
ulation studies, possibly using only published graphs of out-
come probability over time for control groups, as explained by 
Allignol et al [46].
In addition, novel statistical methods will be tested that 
allow historical control data from a single study (as compared 
with multiple studies, recommendation 7) to be used in future 
RCTs [12]. Outcome estimates from a single previous trial can 
be weighted depending on similarity to the outcome in the 
new trial, thereby increasing sample size and power with only 
a limited increase in type I  error. This may help demonstrate 
the totality of evidence to reviewers, by including the relevant 
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historical data in a secondary analysis. This new approach can 
also be extended to multiple historical studies [11] and as such 
is a promising alternative to the methods listed in recommen-
dation 7, because it is more flexible and does not require the 
strong assumptions about heterogeneity and exchangeability.
Finally, efforts to initiate an antibacterial platform trial 
(recommendation 8)  are underway in both the EU, through 
COMBACTE-NET and PREPARE, and the United States, 
through the Antibiotics Resistance Leadership Group (www.
arlg.org), and also globally, through the Wellcome Trust. 
Additional simulation work to understand operating charac-
teristics and further discussions with regulatory agencies on a 
case-by-case basis will be needed to continue to progress and 
embed these innovative trials.
The work presented here was bound by the IMI call text and 
the subsequent description of work. Since 2012, the landscape 
has changed, and a multitude of methodological approaches 
for accelerated antibacterial development have been proposed. 
Rex et al [7] have discussed the 4-tiered approach to registra-
tion, whereby required strength of the evidence depends on 
the severity of the unmet medical need, ranging from disease 
focused double phase III RCTs to pathogen-focused obser-
vational studies. Although the current regulatory framework 
seems more open for these alternative routes, acceptance still 
requires alignment and assessment of unmet medical need. 
For PK/PD data, the European Medicines Agency has recently 
updated their guidance document [21], and sponsors are now 
encouraged to include and use PK/PD data in their applica-
tion for regulatory approval of new antibiotics, although this 
is, unfortunately, not yet fully adopted in all current application 
dossiers. In addition, a proper framework for the reassessment 
of old antibiotics is urgently required. Multiple Bayesian appli-
cations have been proposed as well, of which some would fit 
logically within the current regulatory framework; Bayesian-
based meta-analyses could be used to determine more appro-
priate NI margins, while balancing the degree of unmet need 
and the feasibility of the RCT [47].
From an ethical point of view, the possible benefit for society 
should be subordinate to the individual risks of participation 
in research, and should include assessment of operational risks 
of RCTs (eg, too-complex trials stopped due to poor recruit-
ment), and scientific rigor (eg, data validity and power issues). 
To quote Ruberg, “Our professional challenge is to implement 
adaptive approaches while maintaining sufficient rigor in the 
design and analysis of clinical development trials and programs 
without inhibiting innovation or delaying the access of needed 
medications to patients who are waiting.” [48]. Hopefully, these 
recommendations and their continued evaluation and evolu-
tion will accelerate antibacterial approval and ensure appropri-
ate use of established antibiotics to help those in need as soon 
and best as possible.
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